A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib

Adam Craig,H. Kantarjian,J. E. Cortes,Dan Jones,Andreas Hochhaus,Susan O'Brien,Mary Beth Rios,C. Zander,L. Gleich,E. P. Carroll,Oliver G. Ottmann

A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib

2007

Adam Craig
H. Kantarjian
J. E. Cortes
Dan Jones
Andreas Hochhaus
Susan O'Brien
Mary Beth Rios
C. Zander
L. Gleich
E. P. Carroll
Oliver G. Ottmann

7046 Background: INNO-406 is an orally available, dual Abl/Lyn kinase inhibitor that is up to 55-times more potent than imatinib in Bcr-Abl cell lines. Numerous Bcr-Abl mutant proteins (not T315I) ...

Keywords:

Acute lymphocytic leukemia
Refractory
Philadelphia Chromosome Positive
ABL
Cancer research
Imatinib
LYN
Kinase
Ph- Chronic Myelogenous Leukemia
Medicine
Mutant
Pathology
Cell culture

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations